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Abstract
Introduction and hypothesis Intravesically administered lidocaine is used in patients with bladder pain syndrome (BPS) to test
the hypothesis that symptoms have a peripheral versus central mechanism.
Methods A cross-sectional study of 24 female patients with BPS was performed. The Central Sensitisation Inventory (CSI) and
Kings Health Questionnaire (KHQ) were completed. Urodynamic assessment was undertaken.Women were asked to report their
pain using a numeric rating scale at cystometric capacity and post void. Participants then received an intravesical instillation of
either 20 ml of 2% alkalinised lidocaine (n = 16) or 20 ml of normal saline (n = 8). These solutions were allowed to remain in situ
for 20 min and pain score repeated. Urodynamics was repeated.
Results There was a statistically significant volume increase following lidocaine treatment: maximal cystometric capacity (MCC)
192–261 ml post lidocaine (p = 0.005.) In contrast, there was no significant difference in the saline controls: MCC 190–183 ml
(p = 0.879.) Individual analysis revealed five of 16 lidocaine participants did not respond to lidocaine. These five reported a
significantly worse quality of life (QoL) than lidocaine responders and had a tendency towards central sensitivity syndromes.
Conclusion Lidocaine significantly improvedMCC in 11/16 participants in this study. These patients appear to have peripherally
mediated disease. However, the failure of response to treatment in five participants, as well as their tendency towards central
sensitivity syndromes, implies that in this subgroup, a peripheral drive from the bladder is not critical to their pain, suggesting
central nervous system (CNS) pathology. This simple and safe test could be used to stratify patients for research or therapeutic
trials.
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Introduction
Bladder pain syndrome (BPS), also known as interstitial cys-
titis (IC), is a heterogeneous chronic pelvic pain condition. It
is defined by the International Continence Society (ICS) as
Bthe complaint of suprapubic pain related to bladder filling,
accompanied by other symptoms such as frequency or
nocturia in the absence of other proven urinary infections or
other obvious pathology^ [1]. This diagnosis is heavily de-
pendent on patient history of bladder pain in the absence of
confounds arising from other disorders affecting the lower
urinary tract. Diagnosis is therefore often delayed, whilst al-
ternatives are excluded [2]. Once diagnosed, many patients
often try multiple treatment options before finding one that
gives them significant or any relief [3]. However, despite ex-
cellent care, some patients never find effective relief of their
pain, even following extreme interventions such as
cystectomy or urinary diversion, when phantom bladder pain
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or sensations of bladder fullness can persist [4, 5]. Risk factors
for phantom pain include chronic pain, traumatic amputation
and psychological factors.
There are multiple aetiologies about the mechanisms of
BPS symptoms. However, one question is whether they are
peripherally mediated or arise from abnormal processing of
sensory information within the central nervous system (CNS)
and become independent of peripheral inputs. There are pre-
cedents for both of these mechanisms in chronic pain states,
but no consensus with BPS. The peripheral mechanism is
abnormal activity or responsiveness in sensory neurones,
and there is a large evidence base for a variety of mediators,
often inflammatory mediators, producing this kind of change
in peripheral nociceptors [6]. The central mechanisms may
have a number of components. One is so-called central sensi-
tisation, a potentiation of synaptic transmission of pain-related
signals, best described in the spinal cord but also likely to
occur elsewhere in the CNS [7]. Other CNS mechanisms are
a change in the descending modulatory influences on the spi-
nal processing of pain or the reorganisation of cortical net-
works that ultimately lead to pain sensation [8, 9]. Both of
these can readily help explain abnormal sensory events, such
as on-going pain and hyperalgesia, but in different patients,
different mechanisms may predominate.
It is both of intellectual and practical interest to understand
what is affecting patients with BPS. The practical benefit is
that it would potentially help in selecting therapies for indi-
vidual patients. In this study, the hypothesis that the pain of
BPS is driven by a combination of both peripheral and central
mechanisms is examined. Our aim was to evaluate the effect
of intravesically administered local anaesthetics on perceived
pain and urodynamic volumes in patients with BPS.
Urodynamics, an objective measure of bladder functionality,
is used to assess bladder response to lidocaine instillation in
BPS. This is the gold standard examination for the assessment
of lower urinary tract disorders. Urodynamics is used in this
study to reduce participant performance bias and the placebo
effect related to lidocaine treatment. In patients in whom the
pain is centrally driven and independent of peripheral pathol-
ogy, it is hypothesised that instillation of local anaesthetics
will not have an effect on perceived pain or urodynamic vol-
umes and bladder capacity.
Materials and methods
This study was approved by the Cork Research Ethics
Committee of the University College Cork and performed at
the Cork University Maternity Hospital (CUMH) tertiary re-
ferral centre, a European Urogynaecological Association
subspecialty-accredited centre in conjunction with the
University of Cork. Analysis was performed at King’s
College London.Written informed consent was obtained from
all participants. Patients with a history of bladder pain accom-
panied by at least one other symptom, such as urinary frequen-
cy, urgency or nocturia, present for at least 3months, as per the
International Continence Society (ICS) definition of BPS,
were recruited into the study [1]. Women with lidocaine hy-
persensitivity or other proven forms of cystitis such as infec-
tive, chemical or radiation cystitis, or neurological disease
such as multiple sclerosis, Parkinson’s disease, spinal cord
injury or neural tube defects, affecting bladder function were
excluded. Also excluded were women with severely debilitat-
ing or concurrent medical or psychiatric conditions that could
influence reporting. Women who were unable to void sponta-
neously, those receiving local anaesthetic analogue therapy or
women with a history of chronic pelvic pain conditions such
as endometriosis, were also excluded.
Participants completed the validated King’s Health
Questionnaire (KHQ) that evaluates the impact of disease on
patient quality of life (QoL) (Appendix 1). In addition, partici-
pants completed the Central Sensitisation Inventory (CSI), Part B
Questionnaire, a validated patient-reported screening instrument
formulated by the University of Texas, USA, to identify patients
whose symptoms may be related to a central sensitivity syn-
dromes (CSS) [10]. In the absence of any other scoring system
in place for central sensitisation, this psychometric tool qualifies
as a valuable screening instrument for clinicians to aid the iden-
tification of patients with CSS (Appendix 2).
Urodynamic assessment was performed to rule out detrusor
overactivity (DO). Urodynamics evaluates the effect of blad-
der filling on bladder function and sensory processing. Since
the pain of BPS manifests primarily during bladder filling,
performing this study during urodynamic examination is the
optimal approach for analysing the mechanisms of pain asso-
ciated with BPS. Urodynamics was performed by the
urogynaecology specialist midwife using the standardised
ICS recommendations [11].
Two catheters were inserted: one into the bladder via the
urethra and the second into the vagina. The bladder was filled
at a rate of 80 ml/min using 0.9% normal saline, as per ICS
recommendations [11]. During the filling phase, the following
indices were recorded: first sensation, normal desire, strong
desire, maximal cystometric capacity (MCC), and cystometric
capacity (CC). MCC is defined as the volume at which the
patient feels she can no longer delay micturition; CC is the
bladder volume at the end of the filling; it is the volume voided
plus any residual urine [11]. Subsequently, an 11-point numer-
ic rating scale (NRS), which measures pain intensity from 0
(no pain) to 10 (worst possible pain), was performed at MCC
and CC (Appendix 3). Bladders were emptied and the pain
score repeated. Participants with any of the following
urodynamic findings were allowed to continue with the inves-
tigation: low compliance as seen on urodynamic tracing, early
sensations or bladder pain on filling (pain score > 5 on NRS at
CC). Participants with no abnormality detected on
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urodynamics were excluded from the study at this stage, as
they were deemed unlikely to have BPS with normal filling
volumes and insignificant pain score at CC.
Subsequently, each study participant was randomly
assigned to receive either 20 ml of 2% alkalinised lidocaine
or 20 ml of 0.9% normal saline into their bladders. The lido-
caine was alkalinised by the CUMH pharmacy department as
follows: 3 ml of sodium bicarbonate dissolved in 9 ml of 0.9%
saline mixed with 8 ml of 2% lidocaine. To assign either
alkalinised lidocaine or saline, a pre-prepared note with
alkalinised lidocaine or saline was picked from an envelope
by the investigator. Participants were blinded to the treatment
received. Solutions were instilled into the bladder using the
already present urodynamic bladder catheter and allowed to
remain in situ for 20 min, at the end of which the numeric pain
score was again recorded. Finally, the urodynamic assessment
as above was repeated. These urodynamic indices are appli-
cable, consistent and reproducible and are thus used to evalu-
ate response to instillation with either lidocaine or saline.
In this study, there was a discrepancy in the number of
patients treated with lidocaine vs saline, with a 2:1 difference.
This is because the main question evaluated was the difference
in response to lidocaine bladder instillation. Urodynamic pa-
rameters are prone to accommodation. Hence, participants
who received saline were present to demonstrate what no
treatment with local anaesthetic should appear like on subse-
quent urodynamic distension: they therefore represent the
control group. Rather than healthy controls, patients with
BPS were chosen so comparisons could be made on the ef-
fects of saline and lidocaine on urodynamic distention pat-
terns. Consequently, by studying the one disease state, vari-
ability in urodynamic test results could be reduced and saline
controls used as a reference group.
Post urodynamics, all participants were referred for cystos-
copy. Though hydrodistension is a therapeutic strategy in BPS
management, in this study, cystoscopy was performed for di-
agnostic purposes, to check for BPS and to exclude any other
bladder or urethral pathologies.While under general anaesthe-
sia, the patient’s bladder was filled by placing a bag of saline
80 cm above the bladder and allowing distension under grav-
ity. The European Society for the Study of IC/BPS (ESSIC)
criteria for cystoscopic BPS diagnosis and assessment was
followed, providing a structured scoring system for cystoscop-
ic findings [12]. These include reduced bladder capacity,
glomerulations, Hunner’s lesions and petechial haemorrhages.
Power analysis was conducted using a priori sample size
calculator for Student’s t test. To reach a power of 80%, a
sample size of 16 patients in the lidocaine group was calculat-
ed, with an alpha level of 0.05 and an effect size of 0.9 derived
from previously reported data of lidocaine effect on BPS/IC
by Nickel et al. [13]. Analysis using Student’s t test was per-
formed for urodynamic tests volumes. Two-way analysis of
variance (ANOVA) was used to compare patient groups and
volumes. P value of <0.05 was deemed statistically signifi-
cant. As pain scores are categorical data, the non-parametric
Mann–WhitneyU test was used to calculate pain scores on the
numeric rating scale. Means with standard deviation (SD) are
used to describe pain scores, and a frequency distribution of
responses table is presented.
Results
Forty-six female patients were screened for inclusion in the
study following referral from the Gynaecology Outpatients
Department. Thirty-four participants (74%) met inclusion
and exclusion criteria. Twelve of the 46 patients (26%) recruit-
ed were not ultimately included either because they presented
no features suggestive of BPS on urodynamics and excluded
following the first urodynamic examination (n = 4) or had no
cystoscopic evidence of disease (n = 8). A further ten (21.7%
of total number screened for inclusion) were excluded follow-
ing the first urodynamic examination, as they were unable to
tolerate the pain associated with urodynamic distension and
requested that they not proceed further with the protocol and
be removed from the study. The remaining 24 participants had
a history of bladder pain for at least 3 months. There was
obvious correlation between patient age, parity, body mass
index (BMI) and risk-factor assessment. No participant had
concurrent lower urinary tract disorders or any other chronic
pain disorders, and all midstream urine specimens were nor-
mal. All showed one or more signs suggestive of BPS on
urodynamics and were allowed to complete the study; 16 were
assigned to receive alkalinised lidocaine and eight normal sa-
line. All participants had evidence of BPS on cystoscopy.
Pain score
Following the first urodynamic distension, mean initial pain
score was reduced post void from the CC values for both the
lidocaine and saline groups. This was further significantly
reduced following a 20-min treatment with intravesically ad-
ministered lidocaine: Z-score 2.0917, p 0.018. There was no
significant difference in pain scores post saline treatment: Z-
score 0.367, p 0.356 (Fig. 1). Of note, there was no difference
in frequency distribution of pain score post void between
groups prior to treatment. There was no change in bladder
compliance in either group. Thus, the group as a whole exhib-
ited a significant effect of lidocaine on pain scores but no
effect of saline (Table 1).
Urodynamic volumes
There was a statistically significant volume increase in all
urodynamic sensation volumes after alkalinised lidocaine
treatment: first desire, normal desire, strong desire, MCC
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and CC. In contrast, there was no statistically significant dif-
ference in any urodynamic parameter following saline treat-
ment (Fig. 2).
Individual pain score analysis
Individual pain scores to determine participant response to
alkalinised lidocaine was evaluated. Five participants had ei-
ther no change or less than a 50% reduction in pain score
following alkalinised lidocaine, indicating bladder instillation
did not significantly reduce their reported pain. This group
were designated lidocaine non-responders (Fig. 3).
Lidocaine responders versus non-responders
During the second urodynamic distension, mean MCC was
significantly increased in those who responded to lidocaine
treatment (p = 0.007). This was not observed in the five non-
responders (p = 0.89) (Fig. 4a). Unlike responders, in non-re-
sponders, all urodynamic parameters and volumes were
unaffected, but followed the urodynamic dissension pattern
of participants post-saline instillation (Fig. 4b). On cystoscop-
ic examination, there was no difference in disease severity in
non-responders versus responders. Glomerulation, petechial
haemorrhage and bladder hyperaemia were present in all par-
ticipants, and there was no difference in bladder capacity in
either group.
Quality of life and central sensitivity index
Non-responders to alkalinised lidocaine reported a significant-
ly worse QoL than responders on the KHQ: mean response
1.83 and 0.6, respectively; p = 0.028. In addition, they had a
significantly higher mean score on pain bother: 3.0 and 2.31,
respectively; p = 0.044 (Appendix 5). Review of the CSI ques-
tionnaire revealed that non-responders were 2.7 times more
likely to have other chronic pain syndromes than responders:
relative risk (RR) 2.769, 95% CI 1.81–4.23, p < 0.0001; num-
ber needed to treat (non-responders) 2.609, 95% CI 4.377–
1.858. Total concomitant CSS diagnoses were made in 24
lidocaine non-responders versus 16 in the responders
(Fig. 5). Thus, non-responders were significantly more likely
to have other central sensitisation-related illnesses than
responders.
Discussion
This study was aimed at evaluating the effect of intravesically
administered local anaesthetics on perceived pain and
urodynamic parameters in patients with BPS. Urodynamic dis-
tension and participant blinding was used to assess the impor-
tance of mechanisms underlying the pain. The study hypothesis
was that patients with centrally mediated disease would not re-
spond to local anaesthetic instillation into the bladder. A total of
five participants, who did not respond to lidocaine treatment,
were identified. They had more severe disease symptomatology
and a higher tendency towards CSS than those who responded.
These results support the hypothesis that although BPS is a dis-
ease of peripheral origin, there exists a group for whom there is a
combination of both peripherally and centrally mediated pain-
signalling mechanisms and a minority in whom central mecha-
nisms dominate. For these women, it is likely that pain process-
ing has become centralised (i.e. dominated by central pathologies
in sensory processing), thus rendering peripheral treatment strat-
egies ineffective.
Though patient reports remain valuable, it is open to subjec-
tive bias and inaccuracies due to misunderstanding the protocol
or requirements. Patient reports in studies involving use of
analgaesics or local anaesthetics are also open to participant per-
formance bias and the placebo effect [14]. For that reason, use of
urodynamics in this study removes participant performance or
reporting bias and reduces variability in reporting. This repre-
sents the main strength of this study. Urodynamics were also
used for BPS diagnosis, with patients (n = 4)with no urodynamic
features of BPS being excluded. This was done to reduce the risk
of studying patients with presumed bladder pain due to extra-
urinary disease. Subsequently, these four patients had cystos-
copies, which additionally confirmed no evidence of BPS.
Intravesically administrated lidocaine is one way to assess
the relative contribution of peripheral versus central patholo-
gies in BPS patients. It is a non-selective voltage-gated sodi-
um channel blocker that blocks all nerve fibres, including
motor, sensory and autonomic fibres, consequently reducing
neuronal depolarisation [15, 16]. Thus, the net effect of
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Fig. 1 Mean numeric pain score at cystometric capacity, post void and
post lidocaine or saline treatment ±1 standard error of the mean (SEM),
calculated using the Mann–Whitney U Test. There is a significant de-
crease in pain score following lidocaine treatment (n = 16), which was
not apparent post saline treatment (n = 8). Statistical analysis performed
using the Mann–Whitney U test, with a U value of 72 (p = 0.0183) post
lidocaine and U value of 30 (p = 0.356) post saline
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lidocaine is complete sensory and motor block, including pa-
ralysis, loss of autonomic function and loss of all sensations. It
remains the most powerful way of blocking pain while
retaining consciousness. In the bladder, this nerve blockade
means modulation of detrusor nerves, making lidocaine effec-
tive in the treatment of BPS. It has been used previously in the
investigation and treatment of BPS. However, the effects of its
use are mainly subjective, relying on patient reports of de-
creased pain and urinary frequency [17, 18]. Those reports
are also subject to placebo effects [19, 20]. Accordingly, com-
bining the predictable and known effects of lidocaine with
objective bladder function testing using urodynamics is a
unique feature of this study.
Lidocaine is a weak base provided in an acidic aqueous so-
lution. Following tissue injection, the anaesthetic is buffered by
the surrounding tissue and converted to the lipid-soluble base
form, allowing for tissue penetration [21]. With intravesical in-
stillation, this buffering by the tissue does not occur, as urine is
acidic, and most of the local anaesthetic remains trapped in the
urine in the acidic state. Lidocaine alkalinised with sodium bi-
carbonate to aid tissue penetration was used. This buffers the
urine, allowing for conversion to the base form and subsequent
enhanced tissue penetration [22]. Serum lidocaine levels are
shown to be significantly higherwith intravesically administered
alkalinised lidocaine than the non-alkalinised form [23].
Alkalinised lidocaine is reported to have tissue absorption suffi-
cient to block the sensory neuron within the submucosal plexus
of the bladder [24]. Adequate lidocaine absorption can therefore
be expected, excluding the uncertainty of non-response due to
insufficient lidocaine serum levels.
Central sensitisation is the Baugmentation of responsive-
ness of central pain-signalling neurons to inputs from low-
Table 1 Pain Scores of individual
participants Post void, n = 16 Post void, n = 8
Pain score: 0–10 Frequency % distribution Pain score: 0–10 Frequency % distribution
0 3 18.8% 0 3 37.5%
1 1 6.3% 1 1 12.5%
2 3 18.8% 2 1 12.5%
3 2 12.5% 3 0 0%
4 4 25.0% 4 1 12.5%
5 1 6.3% 5 1 12.5%
6 1 6.3% 6 1 12.5%
7 0 0% 7 0 0%
8 0 0% 8 0 0%
9 0 0% 9 0 0%
10 1 6.3% 10 0 0%
Mean = 3.125 Mean = 2.25
STD = 2.6 STD= 2.4
Post lidocaine, n = 16 Post saline, n = 8
Pain score: 0–10 Frequency % distribution Pain score: 0–10 Frequency % distribution
0 9 56.3% 0 3 37.5%
1 0 0% 1 1 12.5%
2 3 12.5% 2 2 25%
3 2 12.5% 3 0 0%
4 1 6.3% 4 2 25%
5 0 0% 5 0 0%
6 0 0% 6 0 0%
7 0 0% 7 0 0%
8 0 0% 8 0 0%
9 1 6.3% 9 0 0%
10 0 0% 10 0 0%
Mean = 1.562 Mean = 1.625
STD = 2.4 STD= 1.7
Pain Score is measured on an 11-point numeric rating pain scale at MCC, CC, post void and following either
lidocaine or saline treatment. There is a statistically significant decrease in pain score post lidocaine treatment,
which is not seen following saline treatment. Statistical test; Mann Whitney U test. MCC =Maximal cystometric
capacity, CC = Cystometric capacity
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threshold mechanoreceptors^ [25]. Chronic pain syndromes
in which central sensitisation is suggested to play a role in
include fibromyalgia, vulvodynia, chronic pelvic pain, irrita-
ble bowel syndrome and migraine. These conditions are mu-
tually associated, with the presence of one syndrome accom-
panying another. Together, they are termed CSS, describing a
group of medically indistinct syndromes with a pathology in
which central sensitisation plays a significant role [26]. Use of
the central sensitisation inventory in this study defined the
presence of a higher incidence of other CSS in those not
responding to alkalinised lidocaine compared with those
who responded to treatment. These findings are similar to
the published literature evaluating the role of central sensiti-
sation in BPS pathology [27]. Correlation of CSS scores to
urodynamic findings represents another strength of this study.
Phantom pain is a sensation of pain described by the indi-
vidual as related to a limb or organ that is not physically
present. This, too, is hypothesised to be as a result of central
sensitisation mechanisms [28]. It occurs in 80–100% of am-
putees and is also present postsurgical removal of viscera.
Patients with BPS occasionally complain of phantom bladder
pain or sensations of bladder fullness post cystectomy or
urinary diversion [4, 5]. Thus, attempts at eliminating BPS
pain using either local anaesthetics or surgical excision of
the bladder will not relieve pain perception if there is pain
centralisation. With central sensitisation, although it feels as
if the pain originates in the periphery, it is actually a manifes-
tation of abnormal sensory processing within the CNS. It is
possible that the lack of response to alkalinised lidocaine treat-
ment in combination with the increased prevalence of other
CSS in this group is due to pain-related factors remote from
the periphery, such as central sensitisation. Speculation is
drawn about the plausible role of central sensitisation in BPS.
ESSIC criteria for the diagnosis of BPS recommends
performing cystoscopy with hydrodistension to confirm BPS
and rule out any confusable diseases of the lower urinary tract
[29]. All recruited participants were referred for cystoscopy
where BPS/IC was diagnosed (as evidenced by petechial
haemorrhages). Bladder biopsy is not a prerequisite for diag-
nosis of BPS and was not performed. However, other pelvic
pain disorders, such as endometriosis or pelvic inflammatory
disease, could account for the symptoms described and pres-
ent as pain. These cannot be excluded without diagnostic lap-
aroscopy. Thus, meticulous history taking to exclude patients
Fig. 2 Mean volume for each
sensation felt ± 1 standard error of
the mean (SEM) for the first
urodynamic examination and for
the lidocaine and saline treatment
urodynamics. Significance for
each sensation volume was cal-
culated using paired Student’s t
test pre- and post treatment, and
for the difference between
urodynamic examinations using
two-way analysis of variance
(ANOVA). UDS urodynamic,
MCC maximal cyctometric ca-
pacity, CC cystometric capacity
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whose presenting symptoms were suggestive of extra-urinary
disease was made a priority of recruitment and inclusion in the
study. Of course, with the presence of inadvertent concomitant
extra-urinary pain disorders, intravesically administered lido-
caine is not expected to alleviate the pain.
We additionally used urodynamics for identification of
BPS patients. Bladder compliance can either be normal or
low. Low compliance, due to changes in viscoelastic proper-
ties of the bladder secondary to chronic inflammation, can be
attributed to certain clinically relevant conditions, such as neu-
rogenic bladder, radiation cystitis and BPS. All women with a
history of neurological disorders that may predispose to neu-
rogenic bladder, as well as women with radiation cystitis, were
excluded at recruitment. Consequently, the finding of low
compliance in this cohort, backed up by pain history and re-
duced bladder volumes, is further suggestive of BPS. Of note,
only one participant had anMCC > 300ml. She, however, had
a pain score of 10 at MCC, low compliance and reduced
sensations. She also had cystoscopic evidence of BPS and
was thus included in the analysis.
To identify lidocaine responders versus non-responders,
the difference in numeric pain scores pre- and post-lidocaine
treatment was computed. Previous studies used a 50% reduc-
tion in pain score as a cutoff measure of non-responders [19,
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as perceived by participants in
pre- and post treatment ±1 stan-
dard error of the mean (SEM). b
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Fig. 3 Mean numeric pain scores for each group following either
lidocaine or saline treatment. The lidocaine treatment group are divided
into responders and non-responders. Significance calculated using two-
way analysis of variance (ANOVA) with Bonferroni multiple test com-
parison. ** p < 0.01, ***p < 0.001, ns non-significant.
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23]. This method was therefore used in this study, as it ap-
peared reliable and reproducible and removed the bias of
choosing an arbitrary pain score. In addition, each individual’s
experience of pain is different and unique to that person’s
experiences; thus, a fixed-reference pain score does not repre-
sent a meaningful pain threshold for all individuals. Average
pain score at cystometric capacity was recorded as 9.8 and
reduced post void to 3.1. This is due to the relief gained by
bladder emptying on the BPS pathology. However, one limi-
tation of this study was that ten patients who had severe BPS,
with a pain score >5 on the 10-point scale post-void, were
unwilling to have second urodynamic distension. The study
was hence limited to examining patients with moderate in-
stead of severe disease. However, as the literature suggests,
phantom pain due to pain centralisation is not only present
with severe disease; it can also occur with pain chronicity
and following psychological trauma. It was consequently
deemed appropriate to continue analysis in this moderate-
pain group, as the phenomenon of pain centralisation none-
theless remained valid. Exclusion of these patients also meant
there was a smaller number of participants for final analysis.
However, statistical analysis reached significance despite
these small numbers. Previous publications using lidocaine
in BPS have employed a similar number of participants, with
sufficient power to demonstrate statistical significance [19,
30].
The results of this study allow for consideration of the patho-
physiology of pain associated with BPS. Characterising patients
with BPS in this manner can aid in streamlining treatment strat-
egies. Patients with central dominant pain may receive central
therapies earlier using a multidisciplinary approach to pain man-
agement, while those with peripheral dominant disease may be
managed with peripheral bladder therapies. Additionally, when
all other treatments have failed, prior to radical management
options such as cystectomy or urinary diversion for intractable
pain, this simple technique may distinguish those for whom
phantom bladder pain may persist postoperatively.
Conclusion
Lidocaine use, in this small observational study, allowed for
the evaluation of BPS from a pain perspective. The findings of
this study have important implications for day-to-day practice,
because by using this simple technique to stratify patients into
central or peripheral dominant pain mechanisms or a combi-
nation of both, treatment strategies can be more focused,
bypassing the routine stepwise trial-and-error approach com-
monly used in BPS management. A study evaluating the cen-
tral neural response to invoked bladder pain in BPS patients,
such as those using functional magnetic resonance imaging, is
warranted to confirm the role of central mechanisms in the
BPS pathology. The promising early findings from this study
introduces a setting in which additional recruitment and fur-
ther research will provide confirmation.
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Fig. 5 Lidocaine responders (red)
versus non-responders (grey) and
the presence or absence of con-
comitant central sensitisation
syndromes (CSS) (disease). Non-
responders are significantly more
likely to have concomitant CSS
than responders. Odds ratio
(OR) = 5.423, 95% confidence
interval (CI) = 2.517–11.68, p = <
0.0001
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